ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use ViaNautis’ non-immunogenic polyNaut® nanovesicles that precisely target specific tissues and cell types Cambridge, UK, 28 October, 2024 – ViaNautis Bio ("ViaNautis" or the "Company"), a groundbreaking biotechnology company at the forefront of delivering targeted genetic nanomedicines, today announces a collaboration with ...